SCHEMBL21725465

SCHEMBL21725465

CC(C)c1ccc(F)cc1-n1cccc1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.36
HTR2C P28335 3/20 0.35
HTR2A P28223 2/20 0.35
RECQL P46063 1/20 0.35
P2RX7 Q99572 3/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2A6 P11509 1/20 0.33
FAAH O00519 1/20 0.33
MGLL Q99685 1/20 0.33
F2RL1 P55085 4/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PKM P14618 1/20 0.33
KCNH2 Q12809 1/20 0.32
KDM4E B2RXH2 2/20 0.32
LMNA P02545 1/20 0.32
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21725508 0.78 CYP17A1 (0.40) CYP19A1P2RX7CYP1A2ALDH1A1MAPT
SCHEMBL12891570 0.75 F2RL1 (0.57) CYP1A2F2RL1ALDH1A1MAPTL3MBTL1
SCHEMBL23251399 0.75 MPI (0.41) CYP19A1P2RX7CYP1A2ALDH1A1MAPT
SCHEMBL12190504 0.74 FAAH (0.52) HTR2CCYP1A2FAAHMGLLALDH1A1
SCHEMBL5715769 0.74 CYP19A1 (0.40) CYP19A1P2RX7CYP1A2CYP2A6ALDH1A1
SCHEMBL21725471 0.73 F2RL1 (0.52) F2RL1ALDH1A1MAPTL3MBTL1GAA
SCHEMBL21725561 0.73 F2RL1 (0.52) F2RL1ALDH1A1MAPTL3MBTL1KDM4E
SCHEMBL14883243 0.73 ALK (0.39) HTR2CHTR2ACYP1A2F2RL1
SCHEMBL23717576 0.72 P2RX7 (0.42) CYP19A1P2RX7ALDH1A1MAPTL3MBTL1
SCHEMBL12891574 0.71 NOTUM (0.49) CYP1A2F2RL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2021-04-20 US disclosed
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-01-07 US disclosed
US-10766877-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-09-08 US disclosed
US-20200216415-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2020-07-09 US disclosed
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-31 US disclosed
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R CYP19A1 2220/4885HTR2C 31/4885HTR2A 21/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R CYP19A1 2220/4885HTR2C 31/4885HTR2A 21/4885
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R CYP19A1 2220/4885HTR2C 31/4885HTR2A 21/4885
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R CYP19A1 2220/4885HTR2C 31/4885HTR2A 21/4885
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R CYP19A1 2220/4885HTR2C 31/4885HTR2A 21/4885
US-10766877-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R CYP19A1 2220/4885HTR2C 31/4885HTR2A 21/4885
US-20200216415-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R CYP19A1 2220/4885HTR2C 31/4885HTR2A 21/4885
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R CYP19A1 2220/4885HTR2C 31/4885HTR2A 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.